share_log

B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6

B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6

Bof A證券維持Fate Therapeutics的表現不佳,將目標股價上調至6美元
Moomoo 24/7 ·  03/28 14:13

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ:FATE) with a Underperform and raises the price target from $2 to $6.

B of A Securities分析師塔澤恩·艾哈邁德維持Fate Therapeutics(納斯達克股票代碼:FATE)的表現不佳,並將目標股價從2美元上調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論